Abstract
This paper reviews recent progress in the diagnosis of Alzheimers disease (AD) from electroencephalograms (EEG). Three major effects of AD on EEG have been observed: slowing of the EEG, reduced complexity of the EEG signals, and perturbations in EEG synchrony. In recent years, a variety of sophisticated computational approaches has been proposed to detect those subtle perturbations in the EEG of AD patients. The paper first describes methods that try to detect slowing of the EEG. Next the paper deals with several measures for EEG complexity, and explains how those measures have been used to study fluctuations in EEG complexity in AD patients. Then various measures of EEG synchrony are considered in the context of AD diagnosis. Also the issue of EEG preprocessing is briefly addressed. Before one can analyze EEG, it is necessary to remove artifacts due to for example head and eye movement or interference from electronic equipment. Pre-processing of EEG has in recent years received much attention. In this paper, several state-of-the-art pre-processing techniques are outlined, for example, based on blind source separation and other non-linear filtering paradigms. In addition, the paper outlines opportunities and limitations of computational approaches for diagnosing AD based on EEG. At last, future challenges and open problems are discussed.
Keywords: Alzheimer's disease (AD), mild cognitive impairment (MCI), Electroencephalography (EEG), synchrony, slowing, complexity, differential diagnosis, cognitive decline, medication
Current Alzheimer Research
Title: Diagnosis of Alzheimers Disease from EEG Signals: Where Are We Standing?
Volume: 7 Issue: 6
Author(s): J. Dauwels, F. Vialatte and A. Cichocki
Affiliation:
Keywords: Alzheimer's disease (AD), mild cognitive impairment (MCI), Electroencephalography (EEG), synchrony, slowing, complexity, differential diagnosis, cognitive decline, medication
Abstract: This paper reviews recent progress in the diagnosis of Alzheimers disease (AD) from electroencephalograms (EEG). Three major effects of AD on EEG have been observed: slowing of the EEG, reduced complexity of the EEG signals, and perturbations in EEG synchrony. In recent years, a variety of sophisticated computational approaches has been proposed to detect those subtle perturbations in the EEG of AD patients. The paper first describes methods that try to detect slowing of the EEG. Next the paper deals with several measures for EEG complexity, and explains how those measures have been used to study fluctuations in EEG complexity in AD patients. Then various measures of EEG synchrony are considered in the context of AD diagnosis. Also the issue of EEG preprocessing is briefly addressed. Before one can analyze EEG, it is necessary to remove artifacts due to for example head and eye movement or interference from electronic equipment. Pre-processing of EEG has in recent years received much attention. In this paper, several state-of-the-art pre-processing techniques are outlined, for example, based on blind source separation and other non-linear filtering paradigms. In addition, the paper outlines opportunities and limitations of computational approaches for diagnosing AD based on EEG. At last, future challenges and open problems are discussed.
Export Options
About this article
Cite this article as:
Dauwels J., Vialatte F. and Cichocki A., Diagnosis of Alzheimers Disease from EEG Signals: Where Are We Standing?, Current Alzheimer Research 2010; 7 (6) . https://dx.doi.org/10.2174/156720510792231720
DOI https://dx.doi.org/10.2174/156720510792231720 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders
Current Aging Science Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Inhibitory Mechanism of An Anticancer Drug, Bexarotene Against Amyloid β Peptide Aggregation: Repurposing Via Neuroinformatics Approach
Current Pharmaceutical Design Lipid-lowering Drug Therapy in Elderly Patients
Current Pharmaceutical Design IDO and Clinical Conditions Associated with Depressive Symptoms
Current Drug Metabolism Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Responses of Glial Cells to Stress and Glucocorticoids
Current Immunology Reviews (Discontinued) Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Pharmacological Cyclin-Dependent Kinase Inhibitors (PCIs) as Potential Antiviral Drugs
Anti-Infective Agents in Medicinal Chemistry Editorial (Thematic Issue: Prevention Strategies Targeting Different Preclinical Stages of Alzheimer’s Disease)
Current Alzheimer Research Cellular and Network Mechanisms Underlying Memory Impairment Induced by Amyloid β Protein
Protein & Peptide Letters Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design Treatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches
Current Aging Science Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs
Current Medicinal Chemistry Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Evidence Based Psychosocial Practices and Recovery from Schizophrenia
Current Psychiatry Reviews The Cellular Protective Effects of Rosmarinic Acid: From Bench to Bedside
Current Neurovascular Research Conference Report: 9th Clinical Trials on Alzheimer's Disease (CTAD): Marriott Marquis San Diego Marina, San Diego, CA, USA December 8-10, 2016
CNS & Neurological Disorders - Drug Targets